CPP’s Treatment of Licensed Information Sample Clauses

CPP’s Treatment of Licensed Information. Although the Licensed Information is and remains solely owned by CPP, in recognition of the potential value to TILLOTTS resulting from the confidential nature of certain such Licensed Information, CPP will take reasonable steps, in its good faith discretion and in close consultation with TILLOTTS, to protect Licensed Information by using the degree of care that CPP ordinarily uses for such Licensed Information, subject to (a) obligations that CPP may have or rights that third parties may have, including pursuant to clinical trial site agreements or the Arizona License, to disclose certain Licensed Information, and (b) CPP’s obligations to comply with applicable laws and regulations, including applicable securities laws and the rules of regulations of applicable securities exchanges as well as following an order of a court of competent jurisdiction or a government agency properly exercising its delegated authority which compels CPP to disclose Licensed Information; provided, however, that: (i) the foregoing shall not prevent CPP from disclosing Licensed Information if, in CPP’s reasonable business judgment, such disclosure is appropriate in order to (A) exercise CPP’s rights to develop Licensed Formulations outside the Licensed Territory and within the Licensed Territory outside the Licensed Field, or (B) to provide corporate partners, investors or lenders, or potential corporate partners, investors, lenders or professional financial analysts, information that CPP deems to be relevant to a potential corporate transaction, investment in, or loan to, CPP; and (ii) notwithstanding anything in this Agreement to the contrary, and recognizing that CPP retains all rights to the Licensed Information outside the Licensed Territory, if CPP materially breaches this Subsection 3.2.1(a), then TILLOTTS’ sole remedy for such breach shall be monetary damages or injunctive relief and TILLOTTS shall not be entitled to terminate this Agreement as a result of any breach by CPP of this Subsection 3.2.1(a). For clarity, except for this Subsection 3.2.1(a), the obligations and procedures described in Section 3.2 do not apply to CPP.
Sample 1
AutoNDA by SimpleDocs

Related to CPP’s Treatment of Licensed Information

  • KYC Information (i) Upon the reasonable request of any Lender made at least five (5) days prior to the Closing Date, the Borrowers shall have provided to such Lender, and such Lender shall be reasonably satisfied with, the documentation and other information so requested in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the PATRIOT Act, in each case at least five (5) days prior to the Closing Date.

  • - CLEC INFORMATION CLEC agrees to work with Qwest in good faith to promptly complete or update, as applicable, Qwest’s “New Customer Questionnaire” to the extent that CLEC has not already done so, and CLEC shall hold Qwest harmless for any damages to or claims from CLEC caused by CLEC’s failure to promptly complete or update the questionnaire.

  • Technical Information The Employer agrees to provide to the Union such information that is available relating to employees in the bargaining unit, as may be required by the Union for collective bargaining purposes.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • TRADEMARK INFORMATION You herein acknowledge, understand and agree that all of the LMS50 Corporation trademarks, copyright, trade name, service marks, and other LMS50 Corporation logos and any brand features, and/or product and service names are trademarks and as such, are and shall remain the property of LMS50 Corporation. You herein agree not to display and/or use in any manner the LMS50 Corporation logo or marks without obtaining LMS50 Corporation's prior written consent. COPYRIGHT OR INTELLECTUAL PROPERTY INFRINGEMENT CLAIMS NOTICE & PROCEDURES LMS50 Corporation will always respect the intellectual property of others, and we ask that all of our users do the same. With regards to appropriate circumstances and at its sole discretion, LMS50 Corporation may disable and/or terminate the accounts of any user who violates our TOS and/or infringes the rights of others. If you feel that your work has been duplicated in such a way that would constitute copyright infringement, or if you believe your intellectual property rights have been otherwise violated, you should provide to us the following information:

  • CONFIDENTIAL TREATMENT REQUESTED Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to denote where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Other Confidential Consumer Information Party agrees to comply with the requirements of AHS Rule No. 08-048 concerning access to and uses of personal information relating to any beneficiary or recipient of goods, services or other forms of support. Party further agrees to comply with any applicable Vermont State Statute and other regulations respecting the right to individual privacy. Party shall ensure that all of its employees, subcontractors and other service providers performing services under this agreement understand and preserve the sensitive, confidential and non-public nature of information to which they may have access.

  • CONFIDENTIAL/TRADE SECRET MATERIALS a. Contractor Confidential, trade secret or proprietary materials as defined by the laws of the State of New York must be clearly marked and identified as such upon submission by the Bidder. Marking the Bid as “confidential” or “proprietary” on its face or in the document header or footer shall not be considered by the Commissioner or Authorized User to be sufficient without specific justification as to why disclosure of particular information in the Bid would cause substantial injury to the competitive position of the Bidder. Bidders/Contractors intending to seek an exemption from disclosure of these materials under the Freedom of Information Law must request the exemption in writing, setting forth the reasons for the claimed exemption. Acceptance of the claimed materials does not constitute a determination on the exemption request, which determination will be made in accordance with statutory procedures. Properly identified information that has been designated confidential, trade secret, or proprietary by the Bidder will not be disclosed except as may be required by the Freedom of Information Law or other applicable State and federal laws.

  • Medical Information Throughout the Pupil's time as a member of the School, the School Medical Officer shall have the right to disclose confidential information about the Pupil if it is considered to be in the Pupil's own interests or necessary for the protection of other members of the School community. Such information will be given and received on a confidential, need-to-know basis.

Time is Money Join Law Insider Premium to draft better contracts faster.